NanoVibronix, Inc. (NASDAQ:NAOV) Short Interest Update

NanoVibronix, Inc. (NASDAQ:NAOV) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totalling 34,700 shares, a decrease of 17.4% from the May 31st total of 42,000 shares. Based on an average trading volume of 38,800 shares, the short-interest ratio is currently 0.9 days. Currently, 1.3% of the company’s stock are sold short.

Hedge Funds Weigh In On NanoVibronix

An institutional investor recently bought a new position in NanoVibronix stock. Armistice Capital LLC bought a new position in NanoVibronix, Inc. (NASDAQ:NAOV) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 29,023 shares of the company’s stock, valued at approximately $57,000. Armistice Capital LLC owned 1.75% of NanoVibronix as of its most recent filing with the SEC. Institutional investors and hedge funds own 16.39% of the company’s stock.

NanoVibronix Stock Performance

Shares of NanoVibronix stock traded up $0.02 during midday trading on Tuesday, hitting $0.72. The company had a trading volume of 36,717 shares, compared to its average volume of 69,794. The company has a 50 day moving average of $0.76 and a 200 day moving average of $0.89. NanoVibronix has a 52-week low of $0.67 and a 52-week high of $4.23.

NanoVibronix (NASDAQ:NAOV) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $0.92 million during the quarter. NanoVibronix had a negative return on equity of 95.96% and a negative net margin of 112.35%.

About NanoVibronix

NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.